IR is a key pathogenic component in a variety of metabolic diseases, including type 2 diabetes, and is defined as a reduced responsiveness of insulin-targeted tissues to physiological insulin levels (Armutcu and McCloskey, 2024). This evidence concerns the gene INS and type 2 diabetes mellitus.